{"url_path":"/sec/exoz/8-k/2026-06-17/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/2010788/0001493152-26-029119-index.html","accession_number":"0001493152-26-029119","cik":"0002010788","ticker":"EXOZ","issuer_name":"EXOZYMES INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2010788/0001493152-26-029119-index.html","primary_entity_key":"0002010788","primary_entity_name":"EXOZYMES INC."},"word_count":112,"has_tables":true,"body_markdown":"**Item\n7.01**\n**Regulation\nFD Disclosure**\n\n \n\nOn\nJune 17, 2026, the Company issued a press release announcing the closing of the Offering and exercise of the over-allotment. A copy of\nthe press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.\n\n \n\nThe\ninformation contained in this Item 7.01 shall be considered “furnished” and not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any\nfiling under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}